Trials / Completed
CompletedNCT01251627
Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS · Academic / Other
- Sex
- All
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to assess the activity of decitabine in the treatment of CMML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine | Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles. |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-12-01
- Completion
- 2018-06-01
- First posted
- 2010-12-02
- Last updated
- 2018-06-25
Locations
21 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01251627. Inclusion in this directory is not an endorsement.